Masato Wakakura
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Masato Wakakura has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
Yuko Emoto
Division of Neuro-Ophthalmology, Inouye Eye Hospital, Tokyo
2 shared publicationsA. Yamagami
Division of Neuro-ophthalmology, Inouye Eye Hospital, Tokyo, Japan
1 shared publication- Akihiro Shinkai
Department of Ophthalmology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan
1 shared publication - Akiko Kimura
Kind Eye Clinic, Kobe 650-0022, Japan
1 shared publication - Akiko Masuda
Department of Ophthalmology, Hyogo Medical University, Nishinomiya 663-8501, Japan
1 shared publication Akiko Yamagami
Ophthalmology Inouye Eye Hospital Tokyo JPN
1 shared publication
Latest Publications
- Open Access
Efficacy and Safety of IncobotulinumtoxinA for the Treatment of Blepharospasm: A Multicenter, Phase 3 Study in Japan
This open-label, uncontrolled, single-arm, multicenter, phase 3 study evaluated the efficacy and safety of incobotulinumtoxinA in Japanese patients with blepharospasm. Eligible patients received incobotulinumtoxinA injections at fixed doses (50, 75, or 100 units [U] for those who had previously received botulinum toxin treatment; 50 U for treatment-naïve patients), followed by flexible doses up to 100 U for 48 weeks, with at least 6-week intervals. In total, 29 Japanese patients were enrolled (26 [89.7%] women, mean age 64.6 years, mean baseline Jankovic Rating Scale [JRS] severity score 3.24). The primary endpoint, the least squares mean of change in JRS severity scores from baseline to 6 weeks after the first injection, was −2.08 (95% confidence interval: −2.49, −1.66), meeting the prespecified efficacy criteria. The secondary endpoint results (JRS severity, frequency, and total scores for 48 weeks; Blepharospasm Disability Index; Patient Evaluation of Global Response; and fast blinking test) supported the efficacy of repeated incobotulinumtoxinA injections. Adverse events (AEs) occurred in 19 (65.5%) patients, with eyelid ptosis being the most common treatment-related AE (4 [13.8%] patients). No severe or serious AEs were reported. IncobotulinumtoxinA demonstrated sustained efficacy in Japanese patients with blepharospasm, without new safety concerns. (Japan Registry of Clinical Trials identifier, jRCT2031230711)
Open AccessEfficacy and Safety of IncobotulinumtoxinA for the Treatment of Blepharospasm: A Multicenter, Phase 3 Study in Japan
This open-label, uncontrolled, single-arm, multicenter, phase 3 study evaluated the efficacy and safety of incobotulinumtoxinA in Japanese patients with blepharospasm. Eligible patients received incobotulinumtoxinA injections at fixed doses (50, 75, or 100 units [U] for those who had previously received botulinum toxin treatment; 50 U for treatment-naïve patients), followed by flexible doses up to 100 U for 48 weeks, with at least 6-week intervals. In total, 29 Japanese patients were enrolled (26 [89.7%] women, mean age 64.6 years, mean baseline Jankovic Rating Scale [JRS] severity score 3.24). The primary endpoint, the least squares mean of change in JRS severity scores from baseline to 6 weeks after the first injection, was −2.08 (95% confidence interval: −2.49, −1.66), meeting the prespecified efficacy criteria. The secondary endpoint results (JRS severity, frequency, and total scores for 48 weeks; Blepharospasm Disability Index; Patient Evaluation of Global Response; and fast blinking test) supported the efficacy of repeated incobotulinumtoxinA injections. Adverse events (AEs) occurred in 19 (65.5%) patients, with eyelid ptosis being the most common treatment-related AE (4 [13.8%] patients). No severe or serious AEs were reported. IncobotulinumtoxinA demonstrated sustained efficacy in Japanese patients with blepharospasm, without new safety concerns. (Japan Registry of Clinical Trials identifier, jRCT2031230711)
- Open Access
- 15 October 2025
- Published by Springer Nature in Cureus
- Vol. 17 (10) , e94664
High-Density Glasses in Blepharospasm: Influence of Migraine and Early Morning Effects
Photophobia and somatosensory disorders in patients with benign essential blepharospasm (BEB) are caused by the accumulation of light input to the brain, resulting in persistent eye-opening difficulties. Consecutive patients with photophobia and photosensitivity due to BEB were recruited. The patients were asked to participate in a trial using high-density glasses, with only 1.5% visible light transmittance, produced by Tokai Optical Co. Ltd. (HD glass®) (Aichi, Japan). Patients were instructed to wear glasses 2-3 times per day for 20 min or more in a dimly lit room every day for at least two months. Patients answered a questionnaire on the effects of wearing glasses whilst wearing them (during), approximately 30 min after removing the glasses (after), and two months after the self-trial (two-month). A total of 61 patients (52 women and 9 men) aged 21-81 (51.5±17.4) years were recruited. Early morning effects were identified in 39 patients (64.0%), and a present or previous history of migraine was reported in 29 patients (47.5%). More than half of the patients eventually reported improvement. The improvement rate was significantly higher at all three time points (during, after, and two months) in the group with early morning effects than in the group without early morning effects. Migraines, which are often associated with photophobia, may be a risk factor for BEB. This trial, using high-density glasses to inhibit light input to the brain, proved beneficial, particularly in patients with BEB and early morning effects, increasing their quality of life after two months. However, controlled trials are needed to validate these findings.
- 15 October 2025
- Published by Springer Nature in Cureus
- Vol. 17 (10) , e94664
Open AccessHigh-Density Glasses in Blepharospasm: Influence of Migraine and Early Morning Effects
Photophobia and somatosensory disorders in patients with benign essential blepharospasm (BEB) are caused by the accumulation of light input to the brain, resulting in persistent eye-opening difficulties. Consecutive patients with photophobia and photosensitivity due to BEB were recruited. The patients were asked to participate in a trial using high-density glasses, with only 1.5% visible light transmittance, produced by Tokai Optical Co. Ltd. (HD glass®) (Aichi, Japan). Patients were instructed to wear glasses 2-3 times per day for 20 min or more in a dimly lit room every day for at least two months. Patients answered a questionnaire on the effects of wearing glasses whilst wearing them (during), approximately 30 min after removing the glasses (after), and two months after the self-trial (two-month). A total of 61 patients (52 women and 9 men) aged 21-81 (51.5±17.4) years were recruited. Early morning effects were identified in 39 patients (64.0%), and a present or previous history of migraine was reported in 29 patients (47.5%). More than half of the patients eventually reported improvement. The improvement rate was significantly higher at all three time points (during, after, and two months) in the group with early morning effects than in the group without early morning effects. Migraines, which are often associated with photophobia, may be a risk factor for BEB. This trial, using high-density glasses to inhibit light input to the brain, proved beneficial, particularly in patients with BEB and early morning effects, increasing their quality of life after two months. However, controlled trials are needed to validate these findings.
- 3 October 2022
- Published by Wolters Kluwer Health in Journal of Neuro-Ophthalmology
- Vol. 42 (4) , e602-e603
Obituary of Professor Satoshi Ishikawa (1932–2022)
- 3 October 2022
- Published by Wolters Kluwer Health in Journal of Neuro-Ophthalmology
- Vol. 42 (4) , e602-e603
Obituary of Professor Satoshi Ishikawa (1932–2022)
- 9 January 2018
- Published by Taylor & Francis in Neuro-Ophthalmology
- Vol. 42 (5) , 275-283
Blepharospasm in Japan: A Clinical Observational Study From a Large Referral Hospital in Tokyo
Focal dystonia is regarded as a characteristic feature of blepharospasm. However, patients do not always present with motor symptoms. To clarify the clinical features of blepharospasm in Japan, we conducted a retrospective observational study involving a large population of patients from a single institution. Common symptoms included difficulty opening the eyes, photophobia, and ocular pain/irritation. Initial symptoms often occurred following the long-term use of psychotropics such as etizoram, benzodiazepines, and zolpidem (32% of patients). Our findings demonstrated that the clinical presentation of blepharospasm is heterogenous, and that understanding regarding sensory-dominant forms of the disease may be poor among practitioners in Japan.
- 9 January 2018
- Published by Taylor & Francis in Neuro-Ophthalmology
- Vol. 42 (5) , 275-283
Blepharospasm in Japan: A Clinical Observational Study From a Large Referral Hospital in Tokyo
Focal dystonia is regarded as a characteristic feature of blepharospasm. However, patients do not always present with motor symptoms. To clarify the clinical features of blepharospasm in Japan, we conducted a retrospective observational study involving a large population of patients from a single institution. Common symptoms included difficulty opening the eyes, photophobia, and ocular pain/irritation. Initial symptoms often occurred following the long-term use of psychotropics such as etizoram, benzodiazepines, and zolpidem (32% of patients). Our findings demonstrated that the clinical presentation of blepharospasm is heterogenous, and that understanding regarding sensory-dominant forms of the disease may be poor among practitioners in Japan.
- Open Access
- 1 June 2011
- Published by Taylor & Francis in Drug, Healthcare and Patient Safety
- Vol. 3, 9-14
Twelve cases of drug-induced blepharospasm improved within 2 months of psychotropic cessation
Peer reviewed article authored by (Emoto Y, Emoto H, Oishi E, Hikita S, Wakakura M). Read article or submit your manuscript for publishing.
- 1 June 2011
- Published by Taylor & Francis in Drug, Healthcare and Patient Safety
- Vol. 3, 9-14
Open AccessTwelve cases of drug-induced blepharospasm improved within 2 months of psychotropic cessation
Peer reviewed article authored by (Emoto Y, Emoto H, Oishi E, Hikita S, Wakakura M). Read article or submit your manuscript for publishing.
- 1 November 2009
- Published by Springer Nature in Japanese Journal of Ophthalmology
- Vol. 53 (6) , 603-607
Initial temporal field defect in Leber hereditary optic neuropathy
To determine the site of the initial field defect in patients with Leber hereditary optic neuropathy (LHON). We studied nine eyes of nine consecutive LHON patients with the 11778 mitochondrial DNA mutation who had no visual loss (four eyes) or only minimal visual loss (five eyes). When unilateral visual loss was observed, Humphrey field analysis (HFA) (HFA 30–2 program and sometimes the HFA 10–2 program) was immediately and repeatedly performed on the better eye. For the 12 centralmost points in the visual field, a loss of sensitivity (P < 0.02) was initially found in the upper temporal field of nine eyes and in the lower temporal field of three eyes. These results indicate that it was possible to detect the initial site of sensitivity loss in the centralmost temporal test points in all nine cases. The HFA 10–2 program confirmed the sensitivity loss in the temporal field in two cases. The centralmost temporal visual field appears to be the most susceptible site in eyes of LHON patients. This suggests that the most susceptible cells during the early stages of LHON are the retinal ganglion cells located in the corresponding region of the retina.
- 1 November 2009
- Published by Springer Nature in Japanese Journal of Ophthalmology
- Vol. 53 (6) , 603-607
Initial temporal field defect in Leber hereditary optic neuropathy
To determine the site of the initial field defect in patients with Leber hereditary optic neuropathy (LHON). We studied nine eyes of nine consecutive LHON patients with the 11778 mitochondrial DNA mutation who had no visual loss (four eyes) or only minimal visual loss (five eyes). When unilateral visual loss was observed, Humphrey field analysis (HFA) (HFA 30–2 program and sometimes the HFA 10–2 program) was immediately and repeatedly performed on the better eye. For the 12 centralmost points in the visual field, a loss of sensitivity (P < 0.02) was initially found in the upper temporal field of nine eyes and in the lower temporal field of three eyes. These results indicate that it was possible to detect the initial site of sensitivity loss in the centralmost temporal test points in all nine cases. The HFA 10–2 program confirmed the sensitivity loss in the temporal field in two cases. The centralmost temporal visual field appears to be the most susceptible site in eyes of LHON patients. This suggests that the most susceptible cells during the early stages of LHON are the retinal ganglion cells located in the corresponding region of the retina.
- 1 March 2004
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 75 (3) , 506-507
Etizolam and benzodiazepine induced blepharospasm
- 1 March 2004
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 75 (3) , 506-507
Etizolam and benzodiazepine induced blepharospasm